Compare Danaher Corporation (DHR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Moderna, Inc. — how do they compare? Danaher Corporation trades at $219.12 (market cap $152.87B), while Moderna, Inc. trades at $218.59 (market cap $78.65B). The key difference: Danaher Corporation is the larger of the two by market cap, and Danaher Corporation pays a 0.74% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Moderna, Inc. for 59 Days on average.
| DHR | MRNA | |
|---|---|---|
Market Cap | $152.87B | $78.65B |
Volume | 5,228,698 | 37,373,437 |
Sector | Health | Health |
52-Week High | $242.05 | $203.46 |
52-Week Low | $161.91 | $22.36 |
Typical Hold Time | 69 Days | 59 Days |
Enterprise Value | $175.08B | $74.80B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
